Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.

Zhao L, Liu H, Yu J, Yuan S, Liang H, Wang W, Jiang J, Yu L, Liang L, Chen Z, Chen X, Zhong X, Zheng Y, Li F, Lin T, Zhao M, Chen T, Chen H, Hu Y, Li G

Open source

DOI: 10.1016/j.eclinm.2025.103421
Published: 2025 Sep
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2025.103421,
  title = {Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.},
  author = {Zhao L and Liu H and Yu J and Yuan S and Liang H and Wang W and Jiang J and Yu L and Liang L and Chen Z and Chen X and Zhong X and Zheng Y and Li F and Lin T and Zhao M and Chen T and Chen H and Hu Y and Li G},
  year = {2025},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2025.103421},
  url = {https://doi.org/10.1016/j.eclinm.2025.103421}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.
AU  - Zhao L
AU  - Liu H
AU  - Yu J
AU  - Yuan S
AU  - Liang H
AU  - Wang W
AU  - Jiang J
AU  - Yu L
AU  - Liang L
AU  - Chen Z
AU  - Chen X
AU  - Zhong X
AU  - Zheng Y
AU  - Li F
AU  - Lin T
AU  - Zhao M
AU  - Chen T
AU  - Chen H
AU  - Hu Y
AU  - Li G
PY  - 2025
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2025.103421
UR  - https://doi.org/10.1016/j.eclinm.2025.103421
ER  -

APA

L, Z., H, L., J, Y., S, Y., H, L., W, W., J, J., L, Y., L, L., Z, C., X, C., X, Z., Y, Z., F, L., T, L., M, Z., T, C., H, C., Y, H., & G, L. (2025). Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2025.103421

Source records

pubmed · retrieved 2026-09-26T22:49:25.566Z